Introduction: The XN-550 is a new, automated, compact, haematology analyser de-
| INTRODUCTION
Major advances in scientific technology have given rise to sophisticated automated blood cell analysers which are suitable for large-and medium-sized laboratories as well as smaller, point-of-care testing (POCT) units. These allow faster turnaround times and permit quicker clinical decisions, aiding patient care. Healthcare professionals welcome the use of POCT analysers within medical practice but are often concerned about their widespread use as it is essential to ensure that they are safe and efficacious, while remaining economical.
1,2
The XN-20 (Sysmex Corporation, Kobe, Japan), a high-range analyser, was first evaluated in 2012, 3 and a further evaluation with paediatric samples was performed in 2015. 4 In this study, we evaluated the XN-550, using the XN-20 as a comparator device. Recent evaluations of the XN-550 (published as Letters) used the XN-9000, XE-2100 or XN-3000 as predicate devices. 5, 6 One of these 5 mainly studied healthy normal subjects with some haematological malignancy patients. The second study 6 There is a predilution mode available which can be used to obtain a FBC result from low-volume blood samples. Body fluid mode can also be used for analysis of cerebrospinal, synovial and serous fluids but was beyond the scope of this performance evaluation, which focussed on precision and comparability in a wide range of normal and abnormal peripheral blood samples.
| METHODS
Both analysers were serviced and calibrated using XN-CAL by specialist engineers before the evaluation. The manufacturer's normal quality control (QC Level 2) material was run before each day of work and precision was assessed in accordance with ICSH guidelines.
8
Normal and abnormal patient samples were selected for within-run precision, and commercial normal QC samples were used for both within-and between-run precision (n=6 for each estimation).
In comparability studies, we tested a total of 202 residual K 2 EDTA samples from adults, selected (to give information on each parameter at the extremes of the pathological range) and then anonymized, 
| Statistics
Data were assessed using summary statistics and Pearson correlations; a probability value of P<.05 was considered significant. No outliers were eliminated unless specifically indicated in the Results sections (eg where a few data points were widely separated from the main data group and could potentially have distorted the correlation). Platelet, neutrophil and reticulocyte counts were analysed both as the entire data set and as a separate analysis of samples with low counts. This was performed for two reasons: firstly, as the overall data plots make it difficult to see whether the correlation holds true at low counts, and secondly, because low counts may be critical in clinical decisions. In the case of PLT counts, the critical count for prophylactic PLT transfusion Occasional discrepant results were seen with the monocyte counts.
Identification of monocytes by blood cell counters, flow cytometry and microscopic means is difficult and controversial, especially when abnormal cells are present 15 (which are not always of a monocytic lineage). The observation of weak/poor correlation for monocyte counts has been observed regularly in previous instrument evaluations. 16, 17 For this set of clinically abnormal samples, discrepant results were also occasionally observed for neutrophils and lymphocytes. These sample sets were mainly from leukaemia patients and both instruments generated error flags to help further assess the patient samples.
The limitations of this study are that we did not perform linearity studies or use reference morphological and flow cytometric procedures for WBC differential counts; however, the XN-550 was evaluated against the XN-20, which we have previously studied in detail with full morphology reporting.
3
The simplicity of operation, excellent display design and the precise results of the XN-550 analyser make it a recommendable haematology instrument for POCT services, including stem cell laboratories, a mobile trolley service for specific outpatient clinics and physician style office laboratories.
